Sartorius Inks $2.6 Billion Deal for French Gene-Therapy Tech Firm Polyplus
By Joshua Kirby
Sartorius AG said Friday that it has reached a deal to buy French gene-therapy technology company Polyplus from a group of private investors for around 2.4 billion euros ($2.62 billion)
Strasbourg-based Polyplus should make sales in the double digits of millions of euros in 2023, along with a "substantial" profit margin, Sartorius said.
The company is active in fields including transfection reagents, plasmid design and protein manufacturing, and also has sites in Belgium, the U.S. and China, Sartorius said.
The German pharmaceutical firm will fund the acquisition from investors including Archimed and WP GG Holdings via a bank loan, to be repaid with instruments that could include an equity component, it said.
The transaction should be completed in the third quarter this year, subject to standard approvals and conditions, Sartorius said.
Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby
(END) Dow Jones Newswires
March 31, 2023 03:21 ET (07:21 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening In the Markets This Week
-
Q2 Stock Market Outlook: Contrarian Plays Increasingly Attractive
-
What the Next Bitcoin Halving Means for ETF Investors
-
5 Undervalued Stocks to Buy After They’ve Been Dumped
-
Morningstar Market Insights: Central Banks, Inflation, and Patient Investing
-
Where to Invest In Bonds Now
-
Reddit Stock Surges in IPO
-
Why Big Bank Stocks Are No Longer Cheap
-
What Investors Need to Know About GE’s Spinoff
-
Investors Can Find More Than Gold in the Mining Industry
-
An Ultracheap Stock to Buy in a Rallying Sector
-
Celsius Stock Has Soared 206%. Is It a Buy or a Sell?
-
10 Undervalued Wide-Moat Stocks
-
Investment Opportunities in US Renewable Energy
-
We Just Upgraded These 6 Companies. Is It Time to Buy the Stocks?
-
The Best International Stock Index Funds